Fig. 2

Anti-leukemic activity of XL102 in AML cell lines, primary myeloid blasts and healthy individuals. A The antiproliferative effect of XL102 using different AML cells was determined using CTG assay after 72 h of drug treatment. Values were calculated using GraphPad Prism by log-transforming the data and fitting it to a nonlinear regression. B Antiproliferative analysis of XL102 in patient derived myeloid blasts of de novo (n = 42), relapsed/refractory (n = 12).and mononuclear cells derived from healthy individuals (n = 15) C Comparative analyses of XL102 cytotoxicity in AML blast and healthy PBMC. D Cell apoptosis was measured using a flow cytometry analysis of Annexin/PI staining after 24 h of XL102 treatment at the indicated concentrations in MOLM13 and OCI AML2 cells E Change in expression of antiapoptotic protein after 24 h of drug treatment in AML cells. Induction of cleaved PARP and cleaved Caspase-3 in dose dependent manner. F Change in expression of antiapoptotic protein in patient derived blast after 24 h of drug treatment. All the western blots are performed in triplicates